KR102080142B1 - 목표 분자에 결합력을 갖는 l-형 핵산 및 이를 제조하는 방법 - Google Patents
목표 분자에 결합력을 갖는 l-형 핵산 및 이를 제조하는 방법 Download PDFInfo
- Publication number
- KR102080142B1 KR102080142B1 KR1020197016125A KR20197016125A KR102080142B1 KR 102080142 B1 KR102080142 B1 KR 102080142B1 KR 1020197016125 A KR1020197016125 A KR 1020197016125A KR 20197016125 A KR20197016125 A KR 20197016125A KR 102080142 B1 KR102080142 B1 KR 102080142B1
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- acid molecule
- derivative
- nucleotide
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11000117.9 | 2011-01-10 | ||
| EP11000117 | 2011-01-10 | ||
| PCT/EP2011/002068 WO2011131371A1 (en) | 2010-04-21 | 2011-04-21 | Lipid binding nucleic acids |
| EPPCT/EP2011/002068 | 2011-04-21 | ||
| EP11008467 | 2011-10-21 | ||
| EP11008467.0 | 2011-10-21 | ||
| PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137017897A Division KR20140026357A (ko) | 2011-01-10 | 2012-01-10 | 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190067260A KR20190067260A (ko) | 2019-06-14 |
| KR102080142B1 true KR102080142B1 (ko) | 2020-02-21 |
Family
ID=45464586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197016125A Active KR102080142B1 (ko) | 2011-01-10 | 2012-01-10 | 목표 분자에 결합력을 갖는 l-형 핵산 및 이를 제조하는 방법 |
| KR1020137017897A Ceased KR20140026357A (ko) | 2011-01-10 | 2012-01-10 | 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137017897A Ceased KR20140026357A (ko) | 2011-01-10 | 2012-01-10 | 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9976145B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2663640B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2014504865A (cg-RX-API-DMAC7.html) |
| KR (2) | KR102080142B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103339258A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012206750A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2824073A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012095303A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201401362TA (en) * | 2011-10-21 | 2014-05-29 | Noxxon Pharma Ag | Glucagon binding nucleic acids |
| PT2802660T (pt) | 2012-01-10 | 2020-04-21 | Aptarion Biotech Ag | Novos ácidos nucleicos que se ligam a c5a |
| EP2802659A1 (en) * | 2012-01-10 | 2014-11-19 | Noxxon Pharma AG | Nucleic acids specifically binding cgrp |
| JP2021523454A (ja) | 2018-05-17 | 2021-09-02 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | 毛髪分析のためのシステム及び方法 |
| MX2020012225A (es) | 2018-05-17 | 2021-01-29 | Procter & Gamble | Sistemas y metodos para el analisis de la cobertura del cabello. |
| WO2020005326A1 (en) | 2018-06-29 | 2020-01-02 | The Procter & Gamble Company | Aptamers for personal care applications |
| EP3956451A1 (en) | 2019-04-16 | 2022-02-23 | The Procter & Gamble Company | Aptamers for odor control applications |
| US12039732B2 (en) | 2021-04-14 | 2024-07-16 | The Procter & Gamble Company | Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications |
| EP4306640A1 (en) | 2022-06-21 | 2024-01-17 | TME Pharma AG | Method for treating a tumor in a subject |
| AU2023287476A1 (en) | 2022-06-21 | 2024-12-05 | TME Pharma AG | Methods for treating a tumor in a subject |
| WO2026163091A1 (en) | 2025-01-29 | 2026-08-06 | ENEA - Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile | Stage-specific combined fecal microrna panels as biomarkers for early diagnosis, clinical stratification and monitoring of alzheimer's disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049828A1 (en) * | 2003-11-10 | 2005-06-02 | Noxxon Pharma Ag | Nucleic acids specifically binding bioactive ghrelin |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| ATE452655T1 (de) | 2001-06-10 | 2010-01-15 | Noxxon Pharma Ag | Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung |
| EP1438321B1 (de) | 2001-10-26 | 2010-05-26 | Noxxon Pharma AG | Modifizierte l-nukleinsäure |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| WO2003070823A2 (en) | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
| AU2004230927B9 (en) | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| KR101189555B1 (ko) | 2004-02-09 | 2012-10-16 | 주프라몰 파렌테랄 콜로이츠 게엠베하 | 폴리사카라이드 및 폴리뉴클레오티드로부터 접합체를제조하는 방법 |
| CA2786794C (en) | 2004-03-23 | 2017-09-12 | Complex Biosystems Gmbh | Aromatic polymeric cascade prodrug linker reagent |
| US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
| EP1807092B1 (en) | 2004-11-05 | 2016-09-07 | The Children's Hospital of Philadelphia | Biodegradable linkers for molecular therapies |
| US20090075342A1 (en) | 2005-04-26 | 2009-03-19 | Sharon Cload | Metabolic profile directed aptamer medicinal chemistry |
| DK1948822T3 (da) * | 2005-10-07 | 2011-10-17 | Johnson & Johnson Res Pty Ltd | Multikomponent-nukleinsyreenzymer og fremgangsmåder til deres anvendelse |
| US20120101267A1 (en) | 2005-10-07 | 2012-04-26 | Alison Velyian Todd | Multicomponent nucleic acid enzymes with cleavage, ligase or other activity and methods for their use |
| WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| WO2008122084A1 (en) | 2007-04-05 | 2008-10-16 | Johnson & Johnson Research Pty Limited | Nucleic acid enzymes and complexes and methods for their use |
| EP2318425A2 (en) * | 2008-07-28 | 2011-05-11 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 9 expression by antisense oligonucleotides |
| US8871920B2 (en) | 2010-04-21 | 2014-10-28 | Noxxon Pharma Ag | Lipid binding nucleic acids |
-
2012
- 2012-01-10 WO PCT/EP2012/000089 patent/WO2012095303A1/en not_active Ceased
- 2012-01-10 CA CA2824073A patent/CA2824073A1/en not_active Abandoned
- 2012-01-10 EP EP12700093.3A patent/EP2663640B1/en active Active
- 2012-01-10 KR KR1020197016125A patent/KR102080142B1/ko active Active
- 2012-01-10 CN CN201280007720XA patent/CN103339258A/zh active Pending
- 2012-01-10 JP JP2013547842A patent/JP2014504865A/ja active Pending
- 2012-01-10 AU AU2012206750A patent/AU2012206750A1/en not_active Abandoned
- 2012-01-10 US US13/978,804 patent/US9976145B2/en active Active
- 2012-01-10 KR KR1020137017897A patent/KR20140026357A/ko not_active Ceased
-
2017
- 2017-04-05 JP JP2017075557A patent/JP2017148055A/ja active Pending
-
2018
- 2018-05-21 US US15/985,626 patent/US20190367921A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049828A1 (en) * | 2003-11-10 | 2005-06-02 | Noxxon Pharma Ag | Nucleic acids specifically binding bioactive ghrelin |
Non-Patent Citations (1)
| Title |
|---|
| Journal of biological chemistry (2001) 276(38) 35320-35327. |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190367921A1 (en) | 2019-12-05 |
| JP2017148055A (ja) | 2017-08-31 |
| JP2014504865A (ja) | 2014-02-27 |
| US20140350088A1 (en) | 2014-11-27 |
| US9976145B2 (en) | 2018-05-22 |
| EP2663640B1 (en) | 2020-11-04 |
| CA2824073A1 (en) | 2012-07-19 |
| WO2012095303A1 (en) | 2012-07-19 |
| KR20190067260A (ko) | 2019-06-14 |
| KR20140026357A (ko) | 2014-03-05 |
| CN103339258A (zh) | 2013-10-02 |
| EP2663640A1 (en) | 2013-11-20 |
| AU2012206750A1 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2663640B1 (en) | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same | |
| EP1737879B1 (en) | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides | |
| CN103946381B (zh) | Ngf适体及其应用 | |
| US7589073B2 (en) | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics | |
| AU2007276435C1 (en) | SDF-I binding nucleic acids | |
| EP2407558A1 (en) | Methods for the detection of a single- or double-stranded nucleic acid molecule | |
| JP2023068147A (ja) | Epas1関連疾患を治療するための有機組成物 | |
| CN101809154A (zh) | C5a结合核酸 | |
| CN102686729A (zh) | 用于治疗hsf1相关疾病的有机组合物 | |
| WO2013142735A1 (en) | Targeting domain and related signal activated molecular delivery | |
| JP2008512098A (ja) | フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用 | |
| US9163243B2 (en) | Nucleic acids specifically binding CGRP | |
| KR20140083039A (ko) | 글루카곤 결합형 핵산 | |
| Cheng et al. | Oligodeoxyribonucleotide length and sequence effects on intramolecular and intermolecular G-quartet formation | |
| WO2005052121A2 (en) | Multivalent aptamers | |
| EP3065744B1 (en) | A ccl2 antagonist for use in treating proteinuria | |
| CN113383079A (zh) | Cxcl8结合性核酸 | |
| HK1146296A (en) | C5a binding nucleic acids | |
| AU2015255324A1 (en) | Telomerase inhibitors and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 7 |